Management and outcome of obstructive airway complications after lung transplantation - a 12-year retrospective cohort study.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jens Gottlieb reports institutional research grants from Zambon/Breath Therapeutics, German Center of Lung Research, Deutsche Forschungsgemeinschaft. He also received fees for advisory/consultancy from Theravance, Pierre Fabre, Atheneum, Merck, Springer Healthcare, European Research Network, and speaker fees from Novartis, Astra Zeneca, CSL Behring. He owns stock options of Pfizer. He serves as a member of the ScanCLAD study’s data safety monitoring board. All disclosures are unrelated to the current work.: Patrick Zardo reports no disclosures.: Thomas Fuehner reports speaker fees from Novartis and Astra Zeneca."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."